Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v1-EN
Language English English
Date Updated 2020-04-20 2020-02-13
Drug Identification Number 02381842 02381842
Brand name TAMIFLU TAMIFLU
Common or Proper name Oseltamivir Phosphate Oseltamivir Phosphate
Company Name HOFFMANN-LA ROCHE LIMITED HOFFMANN-LA ROCHE LIMITED
Ingredients OSELTAMIVIR OSELTAMIVIR
Strength(s) 6MG 6MG
Dosage form(s) POWDER FOR SUSPENSION POWDER FOR SUSPENSION
Route of administration ORAL ORAL
Packaging size 100 mL glass bottles with a bottle adapter and 1 oral dispenser 100 mL glass bottles with a bottle adapter and 1 oral dispenser
ATC code J05AH J05AH
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2020-03-01 2020-03-01
Actual start date 2020-03-10
Estimated end date 2020-03-31 2020-03-31
Actual end date 2020-04-20
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Roche will manage the supply of current inventory until the end of February. We anticipate availability of new stock by the end of March. Roche will manage the supply of current inventory until the end of February. We anticipate availability of new stock by the end of March.
Health Canada comments